Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TNGX 
Tango Therapeutics Inc (TNGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: TNGX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.88
1 Year Target Price $10.88
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 336.24% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 942.37M USD | Price to earnings Ratio - | 1Y Target Price 10.88 |
Price to earnings Ratio - | 1Y Target Price 10.88 | ||
Volume (30-day avg) 8 | Beta 1.68 | 52 Weeks Range 1.03 - 9.11 | Updated Date 10/14/2025 |
52 Weeks Range 1.03 - 9.11 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1287.87% |
Management Effectiveness
Return on Assets (TTM) -31.74% | Return on Equity (TTM) -76.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 709814299 | Price to Sales(TTM) 38.79 |
Enterprise Value 709814299 | Price to Sales(TTM) 38.79 | ||
Enterprise Value to Revenue 29.22 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 111260247 | Shares Floating 32384520 |
Shares Outstanding 111260247 | Shares Floating 32384520 | ||
Percent Insiders 5.98 | Percent Institutions 110.92 |
Upturn AI SWOT
Tango Therapeutics Inc
Company Overview
History and Background
Tango Therapeutics, founded in 2017, is a biotechnology company focused on discovering and developing innovative cancer therapies. It employs a functional genomics platform to identify novel drug targets and develop precision medicines.
Core Business Areas
- Drug Discovery: Tango's core business revolves around the discovery of novel cancer targets using its proprietary functional genomics platform.
- Drug Development: The company develops therapeutic candidates against identified targets through preclinical and clinical studies.
- Precision Medicine: Tango focuses on developing therapies tailored to specific cancer subtypes based on genetic vulnerabilities.
Leadership and Structure
Tango Therapeutics is led by Barbara Weber, M.D. as President and CEO. The organizational structure consists of research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- TNG908: TNG908 is a MTA-cooperative PRMT5 inhibitor being developed for tumors with MTAP deletion. Currently in Phase 1/2 clinical trials. There is no current market share for this drug. Competitors include companies developing PRMT5 inhibitors.
- TNG462: TNG462 is a novel USP1 inhibitor being developed for BRCA1/2-mutant cancers and other HRD-positive cancers. Currently in Phase 1/2 clinical trials. There is no current market share for this drug. Competitors include companies developing USP1 inhibitors.
Market Dynamics
Industry Overview
The oncology market is characterized by high unmet needs and significant investment in drug development. The industry is driven by advancements in genomics and precision medicine.
Positioning
Tango Therapeutics is positioned as a precision oncology company leveraging functional genomics to identify novel targets. Its competitive advantage lies in its unique target discovery platform and its focus on specific cancer subtypes.
Total Addressable Market (TAM)
The total oncology market is estimated to be hundreds of billions of dollars. Tango's focus on precision medicine and novel targets allows it to address a significant portion of this TAM. The market size for MTAP deleted cancers and BRCA1/2-mutant cancers are substantial subsets of the overall oncology market.
Upturn SWOT Analysis
Strengths
- Proprietary functional genomics platform
- Experienced management team
- Focus on novel cancer targets
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development programs
- Limited revenue generation
- Dependence on financing
- High research and development expenses
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through new target discovery
- Successful clinical trial outcomes
- FDA approval of lead drug candidates
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- TPTX
- GILD
Competitive Landscape
Tango's advantage lies in its unique target discovery platform and focus on precision oncology. However, it faces competition from larger pharmaceutical companies with greater resources and established pipelines.
Growth Trajectory and Initiatives
Historical Growth: Tango's historical growth has been driven by its progress in drug discovery and development, as well as its ability to secure partnerships and funding.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of its drug candidates. Analyst estimates vary based on perceived risk and potential market opportunities.
Recent Initiatives: Recent initiatives include advancing TNG908 and TNG462 through clinical trials, expanding its target discovery platform, and exploring new partnerships.
Summary
Tango Therapeutics is a biotechnology company focused on precision oncology with a unique target discovery platform. It's still early in its development, with no products on the market yet. Strong financial footing from partnerships is key. Clinical trial results and success in expanding its drug pipeline will drive future success; failures or strong competition pose risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data may be estimated and subject to change. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tango Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-09-03 | President, CEO & Director Dr. Barbara L. Weber M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://www.tangotx.com |
Full time employees 155 | Website https://www.tangotx.com | ||
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.